Current treatment options for primary immune thrombocytopenia

References

• Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica93(1), 98–103 (2008).
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood113(26), 6511–6521 (2009).
   PubMed Web of Science ®Google Scholar
• Deane S, Teuber SS, Gershwin ME. The geoepidemiology of immune thrombocytopenic purpura. Autoimmune Rev.9(5), A342–A349 (2010).
   PubMed Web of Science ®Google Scholar
• Blanchette M, Freedman J. The history of idiopathic thrombocytopenic purpura (ITP). Transfus. Sci.19(3), 231–236 (1998).
   PubMedGoogle Scholar
• Louwes H, Zeinali Lathori OA, Vellenga E et al. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am. J. Med.106, 430–434 (1999).
   PubMed Web of Science ®Google Scholar
• Hoffman R, Zaknoen S, Yang HH et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N. Engl. J. Med.312(18), 1170–1174 (1985).
   PubMed Web of Science ®Google Scholar
• Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal auto-antibodies inhibit megakaryocytopoiesis in vitro. Blood102(3), 887–895 (2003).
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Blom NR, van der Want JJ et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood103(2), 500–506 (2004).
   PubMed Web of Science ®Google Scholar
• Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood100(2), 728–730 (2002).
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs68(7), 901–912 (2008).
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin. Hematol.47(3), 243–248 (2010).
   PubMed Web of Science ®Google Scholar
• Ghanima W, Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin. Hematol.47(3), 258–265 (2010).
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood115(2), 168–186 (2010).
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood106(7), 2244–2251 (2005).
   PubMed Web of Science ®Google Scholar
• Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr. Opin. Hematol.14(5), 535–556 (2007).
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb. Haemost.99(1), 4–13 (2008).
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br. J. Haematol.143(1), 16–26 (2008).
   PubMed Web of Science ®Google Scholar
• Metjian A, Abrams CS. New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents. Biologics3, 499–513 (2009).
   PubMedGoogle Scholar
• Chouhan JD, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy30(7), 666–683 (2010).
   PubMed Web of Science ®Google Scholar
• Pizutto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of cooperative Latin American Group on Hemostasis and Thrombosis. Blood64(6), 1179–1183 (1984).
   PubMed Web of Science ®Google Scholar
• Dan K, Gomi S, Kuramoto A, Maekawa T, Nomura T. A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura. Int. J. Hematol.55, 287–292 (1992).
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda D, Gillis S, Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol.91, 1–6 (1994).
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am. J. Med.98(5), 436–442 (1995).
   PubMed Web of Science ®Google Scholar
• Pamuk GE, Pamuk ON, Baslar Z et al. Overview of 321 patients with idiopathic thrombocytopenia purpura. Retrospective analysis of the clinical features and response to therapy. Ann. Hematol.81, 436–440 (2002).
   PubMed Web of Science ®Google Scholar
• Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N. Engl. J. Med.330(22), 1560–1564 (1994).
   PubMed Web of Science ®Google Scholar
• Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol. Dis.26(6), 582–586 (2000).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong RS, Soo YO et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N. Engl. J. Med.349(9), 831–836 (2003).
   PubMed Web of Science ®Google Scholar
• Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann. Hematol.83(12), 764–768 (2004).
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Fazi P, Bernasconi S et al. Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood109(4), 1401–1407 (2007).
   PubMed Web of Science ®Google Scholar
• von dem Borne AE, Vos JJ, Pegels JG, Thomas LL, van der Lelie H. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br. Med. J. (Clin. Res. Ed).296(6617), 249–250 (1988).
   PubMed Web of Science ®Google Scholar
• Godeau B, Zini JM, Schaeffer A, Bierling P. High-dose methylprednisolone is an alternative treatment for adults with autoimmune thrombocytopenic purpura refractory to intravenous immunglobulins and oral corticosteroids. Am. J. Hematol.48, 282–284 (1995).
   PubMed Web of Science ®Google Scholar
• Altintop L, Albayrak D. Oral high-dose methylprednisolone and intravenous immunoglobulin treatments in adult chronic idiopathic thrombocytopenic purpura. Am. J. Hematol.56, 191–192 (1997).
   PubMed Web of Science ®Google Scholar
• Alpdogan O, Budak-Alpdogan T, Ratip S et al. Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br. J. Haematol.103(4), 1061–1063 (1998).
   PubMed Web of Science ®Google Scholar
• Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood51(5), 771–779 (1978).
   PubMed Web of Science ®Google Scholar
• Fujisawa K, Tani P, Piro L, McMillan R. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. Blood81(11), 2872–2877 (1993).
   PubMed Web of Science ®Google Scholar
• Kitchens CS, Pendergast JF. Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. Blood67(1), 203–206 (1986).
   PubMed Web of Science ®Google Scholar
• Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N. Engl. J. Med.320(15), 974–980 (1989).
   PubMed Web of Science ®Google Scholar
• Salama A and Mueller-Eckhardt C. Use of Rh antibodies in the treatment of autoimmune thrombocytopenia. Transfus. Med.6, 17–25 (1992).
   Google Scholar
• Scaradavou A, Woo B, Woloski BM et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood89(8), 2689–2700 (1997).
   PubMed Web of Science ®Google Scholar
• Sandler SG, Mallory D, Trimble J, Nance ST. Intravenous anti-D treatment for immune thrombocytopenic purpura. Blood91(7), 2624–2625 (1998).
   PubMed Web of Science ®Google Scholar
• Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br. J. Haematol.112(4), 1076–1078 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper N, Woloski BM, Fodero EM et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood99(6), 1922–1927 (2002).
   PubMed Web of Science ®Google Scholar
• George JN, Raskob GE, Vesely SK et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am. J. Hematol.74(3), 161–169 (2003).
   PubMed Web of Science ®Google Scholar
• Ramadan KM, El-Agnaf M. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin. Lab. Haematol.27(4), 267–269 (2005).
   PubMedGoogle Scholar
• Gaines AR, Lee-Stroka H, Byrne K et al. Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model. Transfusion49(6), 1050–1058 (2009).
   PubMed Web of Science ®Google Scholar
• Meyer O, Kiesewetter H, Hermsen M, Salama A. Efficacy and safety of anti-D given by subcutaneous injection to patients with autoimmune thrombocytopenia. Eur. J. Haematol.73(1), 71–72 (2004).
   PubMed Web of Science ®Google Scholar
• Kjaersgaard M, Edslev PW, Hasle H. Subcutaneous anti-D treatment of idiopathic thrombocytopenic purpura in children. Pediatr. Blood Cancer53(7), 1315–1317 (2009).
   PubMed Web of Science ®Google Scholar
• Trebo MM, Frey E, Gadner H, Minkov M. Subcutaneous anti-D globulin application is a safe treatment option of immune thrombocytopenia in children. Ann. Hematol.89(4), 415–418 (2010).
   PubMed Web of Science ®Google Scholar
• Mollison’s Blood Transfusion In Clinical Medicine, (11th Edition). Klein HG, Anstee DJ (Eds). Blackwell Science Ltd., Cambridge, UK (2004).
   Google Scholar
• Cheung E, Liebman HA. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics3, 57–62 (2009).
   PubMedGoogle Scholar
• Scaradavou A, Woo B, Woloski BMR et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood89(8), 2689–2700 (1997).
   PubMed Web of Science ®Google Scholar
• Newland AC, Treleaven JG, Minchinton RM, Waters AH. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet1(8316), 84–87 (1983).
   PubMed Web of Science ®Google Scholar
• Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br. J. Haematol.107, 716–719 (1999).
   PubMed Web of Science ®Google Scholar
• Godeau B, Chevret S, Varet B et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multucenter trial. Lancet359, 23–29 (2002).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Eldor A, Kelton JG et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb. Haemost.91(4), 771–778 (2004).
   PubMed Web of Science ®Google Scholar
• Schiavotto C, Ruggieri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of literature. Haematologica78(6 Suppl. 2), 35–40 (1993).
   PubMedGoogle Scholar
• Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J. Am. Soc. Nephrol.8(11), 1788–1794 (1997).
   PubMed Web of Science ®Google Scholar
• Levy Y, Sherer Y, Ahmed A et al. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat. Immun.16, 207–214 (1998).
   PubMedGoogle Scholar
• Imbach P, Lazarus AH, Kühne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang.98(3 Pt 2), 385–394 (2010).
   PubMed Web of Science ®Google Scholar
• Bell WR Jr. Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura. Semin. Hematol.37(1 Suppl. 1), 22–25 (2000).
   PubMed Web of Science ®Google Scholar
• Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann. Hematol.81(6), 312–319 (2002).
   PubMed Web of Science ®Google Scholar
• Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am. J. Hematol.72(2), 94–98 (2003).
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood104(9), 2623–2634 (2004).
   PubMed Web of Science ®Google Scholar
• Vianelli N, Galli M, de Vivo A et al. Gruppo Italiano per lo Studio delle Malattie Ematologiche dell’Adulto. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica90(1), 72–77 (2005).
   PubMed Web of Science ®Google Scholar
• Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica91(8), 1041–1045 (2006).
   PubMed Web of Science ®Google Scholar
• George JN. Management of patients with refractory immune thrombocytopenic purpura. J. Thromb. Haemost.4(8), 1664–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Bresler L, Guerci A, Brunaud L et al. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura: outcome and long-term results. World J. Surg.26(1), 111–114 (2002).
   PubMed Web of Science ®Google Scholar
• Keidar A, Feldman M, Szold A. Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count. Am. J. Hematol.80(2), 95–100 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez-Gamboa L, Mei H, Loddenkemper C et al. Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin. Immunol.130(2), 199–212 (2009).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics106(2 Pt 1), 362–366 (2000).
   PubMed Web of Science ®Google Scholar
• Braendenstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am. J. Hematol.78, 275–280 (2005).
   PubMed Web of Science ®Google Scholar
• Penalvér FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refratory patients. Ann. Hematol.85(6), 400–406 (2006).
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med.146(1), 25–33 (2007).
   PubMed Web of Science ®Google Scholar
• Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter Phase 2 study. Blood112(4), 999–1004 (2008).
   PubMed Web of Science ®Google Scholar
• Zaja F, Baccarani M, Mazza P et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood115(14), 2755–2762 (2010).
   PubMed Web of Science ®Google Scholar
• Montero AJ, McCarthy JJ, Chen G, Rice L. Acute respiratory distress syndrome after rituximab infusion. Int. J. Hematol.82(4), 324–326 (2005).
   PubMed Web of Science ®Google Scholar
• Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann. Hematol.82(9), 585–588 (2003).
   PubMed Web of Science ®Google Scholar
• Ozguroglu M, Turna H. Rituximab-induced tumor progression: does it really happen? Med. Oncol.21(2), 205–206 (2004).
   PubMed Web of Science ®Google Scholar
• Quartuccio L, De Re V, Fabris M et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica91(5), 691–694 (2006).
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a ‘vaccinal effect’ of rituximab. Blood113(16), 3809–3812 (2009).
   PubMed Web of Science ®Google Scholar
• Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin. Hematol.47(2), 170–179 (2010).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymphoma51(6), 983–994 (2010).
   PubMed Web of Science ®Google Scholar
• Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol.28(21), 3525–3530 (2010).
   PubMed Web of Science ®Google Scholar
• Van Meerten T, Hagenbeck A. CD20-therapy: the next generation of antibodies. Semin. Hematol.47(2), 199–210 (2010).
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood116(19), 3705–3714 (2010).
   PubMed Web of Science ®Google Scholar
• Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann. Intern. Med.140(2), 112–120 (2004).
   PubMed Web of Science ®Google Scholar
• Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br. J. Haematol.74(2), 223–228 (1990).
   PubMed Web of Science ®Google Scholar
• Hou M, Peng J, Shi Y et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur. J. Haematol.70(6), 353–357 (2003).
   PubMed Web of Science ®Google Scholar
• Kotb R, Pinganaud C, Trichet C et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur. J. Haematol.75(1), 60–64 (2005).
   PubMed Web of Science ®Google Scholar
• Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am. J. Hematol.81(1), 19–25 (2006).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N. Engl. J. Med.355(16), 1672–1681 (2006).
   PubMed Web of Science ®Google Scholar
• Newland A, Caulier MT, Kappers-Klunne M et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br. J. Haematol.135(4), 547–553 (2006).
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Fujita T, Ozaki M et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J. Clin. Pharmacol.47(12), 1489–1497 (2007).
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet371(9610), 395–403 (2008).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood113(10), 2161–2171 (2009).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med.357(22), 2237–2247 (2007).
   PubMed Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood109(11), 4739–4741 (2007).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet373(9664), 641–648 (2009).
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, Phase 3 study. Lancet DOI: 10.1016/S0140-6736(10)60959-2 (2010) (Epub ahead of print).
   Google Scholar
• Meyer O, Salama A. Infection-related transient loss of response and other early side-effects in chronic ITP during treatment with thrombopoietin mimetics. Oncology (2011) (In Press).
   Google Scholar
• Cuker A, Chiang EY, Cines DB. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia. Curr. Drug Saf.5(2), 171–181 (2010).
   PubMedGoogle Scholar
• Samoylenko A, Byts N, Rajalingam K et al. Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and ERK signalling. Cell Signal.20(1), 154–162 (2008).
   PubMed Web of Science ®Google Scholar
• Baker JE, Su J, Hsu A et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc. Res.77(1), 44–53 (2008).
   PubMed Web of Science ®Google Scholar
• Kalota A, Gewirtz AM. A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. Blood115(1), 89–93 (2010).
   PubMed Web of Science ®Google Scholar
• Kuwana M, Nomura S, Fujimura K et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood103(4), 1229–1236 (2004).
   PubMed Web of Science ®Google Scholar
• Willis F, Marsh JC, Bevan DH et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Haematol.114(4), 891–898 (2001).
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol. Oncol. Clin. North Am.21(4), 743–759 (2007).
   PubMed Web of Science ®Google Scholar
• McMinn JR Jr, Cohen S, Moore J et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am. J. Hematol.73(2), 135–140 (2003).
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Seggewiss R, McCloskey DJ, Boss CA, Dunbar CE, Rick ME. Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura. Haematologica91(2), 277–278 (2006).
   PubMed Web of Science ®Google Scholar
• Fukushima-Shintani M, Suzuki K, Iwatsuki Y et al. AKR-501 (YM477), a novel orally-active thrombopoietin receptor agonist. Eur. J. Haematol.82(4), 247–254 (2009).
   PubMed Web of Science ®Google Scholar
• Desjardins RE, Tempel DL, Lucek R et al. Single and multiple oral doses of AKR-501 (TM477) increase the platelet count in healthy volunteers. Blood108, 145a (2006).
   Google Scholar
• Nakamura T, Miyakawa Y, Miyamura A et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood107, 4300–4307 (2006).
   PubMed Web of Science ®Google Scholar
• Dziewanowska ZE, Matsumoto RM, Zhang JK et al. Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increase platelet counts in healthy male subjects. Blood110, 390a (2007).
   Google Scholar
• Nogami W, Yoshida H, Koizumi K et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica93, 1495–1504 (2008).
   PubMed Web of Science ®Google Scholar
• Punnonen F, Muench M, Spencer JR. Differential effects of a novel non-peptidic thrombopoietin mimetic on proliferation and differentiation of human CD34+ progenitor cells. Blood112, 994 (2008).
   Google Scholar
• Liem-Moolenaar M, Cerneus D, Molloy CJ et al. Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans. Clin. Pharmacol. Ther.84(4), 481–487 (2008).
   PubMed Web of Science ®Google Scholar
• Fredrickson S, Renshaw MW, Lin B et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc. Natl Acad. Sci. USA103, 14307–14312 (2006).
   PubMed Web of Science ®Google Scholar
• Cerneus D, Brown K, Harris R et al. Stimulation of platelet production in healthy volunteers by a novel pegylated peptide-based thrombopoietin (TPO) receptor agonist. Blood106, 363a–364a (2005).
   Google Scholar
• Orita T, Tsunoda H, Yabuta N et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of thrombopoietin receptor. Blood105, 562–566 (2005).
   PubMed Web of Science ®Google Scholar
• Kai M, Motoki K, Yoshida H et al. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nat. Biotechnol.26(2), 209–211 (2008).
   PubMed Web of Science ®Google Scholar
• Peeters K, Stassen JM, Collen D, Van Geet C, Freson K. Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov. Today13(17–18), 798–806 (2008).
   PubMed Web of Science ®Google Scholar